Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions

Current Drug Metabolism

Volumn 11, Issue 8, 2010, Pages 659-666

  Shen, Hong Wu ^a   Jiang, Xi Ling ^a   Winter, Jerrold C ^b   Yu, Ai Ming ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

5 MeO DMT; CYP2D6; Drug interaction; Harmaline; Metabolism; Pharmacogenetics; Pharmacokinetics; Serotonin toxicity

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 METHOXY N,N DIMETHYLTRYPTAMINE; BUFOTENINE; CLORGYLINE; COCAINE; CYTOCHROME P450 2D6; HARMALINE; IPSAPIRONE; KETANSERIN; LYSERGIDE; METHAMPHETAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PINDOLOL; PSYCHEDELIC AGENT; VOLINANSERIN;

ARTICLE; BINDING AFFINITY; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSFORMATION; GENETIC POLYMORPHISM; HUMAN; IC 50; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOGENETICS;

ANIMALS; BUFOTENIN; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; HALLUCINOGENS; HARMALINE; HUMANS; METHOXYDIMETHYLTRYPTAMINES; PHARMACOGENETICS; SEROTONIN RECEPTOR AGONISTS;

EID: 79952354609     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010794233495     Document Type: Article

References (113)

1. Yu, A. M. Indolealkylamines: biotransformations and potential drug-drug interactions. Aaps. J., 2008, 10, 242-253.
2. Pachter, I. J.; Zacharias, D. E.; Ribeiro, O. Indole alkaloids of acer saccharinum (the Silver Maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis. J. Org. Chem., 1959, 24, 1285-1287.
3. Ott, J. Pharmepena-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N, N-dimethyl-tryptamine. J. Psychoactive Drugs, 2001, 33, 403-407. (Pubitemid 34059753)
4. McKenna, D. J. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol. Ther., 2004, 102, 111-129. (Pubitemid 38681011)
5. Gambelunghe, C.; Aroni, K.; Rossi, R.; Moretti, L.; Bacci, M. Identification of N, N-dimethyltryptamine and beta-carbolines in psychotropic ayahuasca beverage. Biomed. Chromatogr., 2008, 22, 1056-1059.
6. Weil, A. T.; Davis, W. Bufo alvarius: a potent hallucinogen of animal origin. J. Ethnopharmacol., 1994, 41, 1-8. (Pubitemid 24053223)
7. Narasimhachari, N.; Heller, B.; Spaide, J.; Haskovec, L.; Meltzer, H.; Strahilevitz, M.; Himwich, H. E. N, N-dimethylated indoleamines in blood. Biol. Psychiatry, 1971, 3, 21-23.
8. Oon, M. C.; Murray, R. M.; Rodnight, R.; Murphy, M. P.; Birley, J. L. Factors affecting the urinary excretion of endogenously formed dimethyltryptamine in normal human subjects. Psychopharmacology (Berl)., 1977, 54, 171-175. (Pubitemid 8172386)
9. Smythies, J. R.; Morin, R. D.; Brown, G. B. Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry. Biol. Psychiatry, 1979, 14, 549-556. (Pubitemid 9210289)
10. Sitaram, B. R.; Blackman, G. L.; McLeod, W. R.; Vaughan, G. N. The ion-pair extraction, purification, and liquid chromatographic analysis of indolealkylamines in human urine. Anal. Biochem., 1983, 128, 11-20. (Pubitemid 13162707)
11. Forsstrom, T.; Tuominen, J.; Karkkainen, J. Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS. Scand. J. Clin. Lab. Invest., 2001, 61, 547-556. (Pubitemid 33702362)
12. Benington, F.; Morin, R. D.; Clark, L. C., Jr. 5-methoxy-N, N-dimethyltryptamine, a possible endogenous psychotoxin. Ala. J. Med. Sci., 1965, 2, 397-403.
13. Nishimura, T.; Gjessing, L. R. Failure to detect 3, 4- dimethoxyphenylethylamine and bufotenine in the urine from a case of periodic catatonia. Nature, 1965, 206, 963-964.
14. Narasimhachari, N.; Heller, B.; Spaide, J.; Haskovec, L.; Fujimori, M.; Tabushi, K.; Himwich, H. E. Urinary studies of schizophrenics and controls. Biol. Psychiatry, 1971, 3, 9-20.
15. Gillin, J. C.; Wyatt, R. J. Evidence for and against the involvement of N, N-dimethyl-tryptamine (DMT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in schizophrenia. Psychopharmacol. Bull., 1976, 12, 12-13.
16. Angrist, B.; Gershon, S.; Sathananthan, G.; Walker, R. W.; Lopez-Ramos, B.; Mandel, L. R.; Vandenheuvel, W. J. Dimethyltryptamine levels in blood of schizophrenic patients and control subjects. Psychopharmacology (Berl)., 1976, 47, 29-32.
17. Takeda, N.; Ikeda, R.; Ohba, K.; Kondo, M. Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. Neuroreport, 1995, 6, 2378-2380. (Pubitemid 26010073)
18. Cichon, S.; Nothen, M. M.; Rietschel, M.; Propping, P. Pharmacogenetics of schizophrenia. Am. J. Med. Genet., 2000, 97, 98-106. (Pubitemid 30257331)
19. Emanuele, E.; Colombo, R.; Martinelli, V.; Brondino, N.; Marini, M.; Boso, M.; Barale, F.; Politi, P. Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. Neuro Endocrinol. Lett., 2010, 31, 117-121.
20. DEA-2009-0008. Placement of 5-Methoxy-N, N-Dimethyltryptamine Into Schedule I of the Controlled Substances Act. http://edocket.access.gpo.gov/2009/ E9-20204.htm (Accessed Sep. 23, 2010).
21. Gillin, J. C.; Tinklenberg, J.; Stoff, D. M.; Stillman, R.; Shortlidge, J. S.; Wyatt, R. J. 5-Methoxy-N, N-dimethyltryptamine: behavioral and toxicological effects in animals. Biol. Psychiatry., 1976, 11, 355-358.
22. Glennon, R. A. Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology, 1990, 3, 509-517.
23. Duvvuri, V.; Risbrough, V. B.; Kaye, W. H.; Geyer, M. A. 5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition. Pharmacol. Biochem. Behav., 2009, 93, 349-353.
24. Fantegrossi, W. E.; Murnane, K. S.; Reissig, C. J. The behavioral pharmacology of hallucinogens. Biochem. Pharmacol., 2008, 75, 17-33. (Pubitemid 350235393)
25. McKenna, D. J.; Towers, G. H. Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview. J. Psychoactive Drugs, 1984, 16, 347-358. (Pubitemid 15177218)
26. Ott, J. Pharmahuasca: human pharmacology of oral DMT plus harmine. J. Psychoactive Drugs, 1999, 31, 171-177. (Pubitemid 29321429)
27. Yu, A. M.; Idle, J. R.; Herraiz, T.; Kupfer, A.; Gonzalez, F. J. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics, 2003, 13, 307-319. (Pubitemid 36724524)
28. Yu, A. M.; Idle, J. R.; Gonzalez, F. J. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug. Metab. Rev., 2004, 36, 243-277. (Pubitemid 38802489)
29. Spencer, D. G., Jr.; Glaser, T.; Traber, J. Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N, N-dimethyltryptamine. Psychopharmacology (Berl)., 1987, 93, 158-166. (Pubitemid 18013050)
30. Glennon, R. A.; Dukat, M.; el-Bermawy, M.; Law, H.; De los Angeles, J.; Teitler, M.; King, A.; Herrick-Davis, K. Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl-and indolylalkylamines. J. Med. Chem., 1994, 37, 1929-1935. (Pubitemid 24233604)
31. Roth, B. L.; Choudhary, M. S.; Khan, N.; Uluer, A. Z. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J. Pharmacol. Exp. Ther., 1997, 280, 576-583. (Pubitemid 27171315)
32. Lamchouri, F.; Settaf, A.; Cherrah, Y.; El Hamidi, M.; Tligui, N.; Lyoussi, B.; Hassar, M. Experimental toxicity of Peganum harmala seeds. Ann. Pharm. Fr., 2002, 60, 123-129. (Pubitemid 34274833)
33. Herraiz, T.; Gonzalez, D.; Ancin-Azpilicueta, C.; Aran, V. J.; Guillen, H. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food. Chem. Toxicol., 2010, 48, 839-845.
34. Boyer, E. W.; Shannon, M. The serotonin syndrome. N. Engl. J. Med., 2005, 352, 1112-1120.
35. Sun-Edelstein, C.; Tepper, S. J.; Shapiro, R. E. Drug-induced serotonin syndrome: a review. Expert Opin. Drug. Saf., 2008, 7, 587-596.
36. Gillman, P. K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol. Psychiatry, 2006, 59, 1046-1051. (Pubitemid 43849654)
37. Shen, H. W.; Wu, C.; Jiang, X. L.; Yu, A. M. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N, N-dimethyltryptamine metabolism and pharmacokinetics. Biochem. Pharmacol., 2010, 80, 122-128.
38. Brush, D. E.; Bird, S. B.; Boyer, E. W. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J. Toxicol. Clin. Toxicol., 2004, 42, 191-195. (Pubitemid 38758532)
39. Sklerov, J.; Levine, B.; Moore, K. A.; King, T.; Fowler, D. A fatal intoxication following the ingestion of 5-methoxy-N, N-dimethyltryptamine in an ayahuasca preparation. J. Anal. Toxicol., 2005, 29, 838-841. (Pubitemid 41803388)
40. Shulgin, A. T.; Shulgin, A. TIKAL The Continuation, Transform Press, Berkeley, CA, 1997.
41. Gallagher, C. H.; Koch, J. H.; Moore, R. M.; Steel, J. D. Toxicity of Phalaris Tuberosa for sheep. Nature, 1964, 204, 542-545.
42. Glennon, R. A.; Titeler, M.; McKenney, J. D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life. Sci., 1984, 35, 2505-2511. (Pubitemid 15212191)
43. Darmani, N. A.; Martin, B. R.; Pandey, U.; Glennon, R. A. Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol. Biochem. Behav., 1990, 36, 901-906. (Pubitemid 20272314)
44. Winter, J. C.; Fiorella, D. J.; Timineri, D. M.; Filipink, R. A.; Helsley, S. E.; Rabin, R. A. Serotonergic receptor subtypes and hallucinogeninduced stimulus control. Pharmacol. Biochem. Behav., 1999, 64, 283-293. (Pubitemid 29438613)
45. Winter, J. C.; Filipink, R. A.; Timineri, D.; Helsley, S. E.; Rabin, R. A. The paradox of 5-methoxy-N, N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol. Biochem. Behav., 2000, 65, 75-82. (Pubitemid 30017998)
46. Winter, J. C. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl), 2009, 203, 251-263.
47. Sadzot, B.; Baraban, J. M.; Glennon, R. A.; Lyon, R. A.; Leonhardt, S.; Jan, C. R.; Titeler, M. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl), 1989, 98, 495-499. (Pubitemid 19193897)
48. Fantegrossi, W. E.; Harrington, A. W.; Kiessel, C. L.; Eckler, J. R.; Rabin, R. A.; Winter, J. C.; Coop, A.; Rice, K. C.; Woods, J. H. Hallucinogen-like actions of 5-methoxy-N, N-diisopropyltryptamine in mice and rats. Pharmacol. Biochem. Behav., 2006, 83, 122-129.
49. Rabin, R. A.; Regina, M.; Doat, M.; Winter, J. C. 5-HT2A receptorstimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol. Biochem. Behav., 2002, 72, 29-37. (Pubitemid 34251305)
50. Matsumoto, K.; Mizowaki, M.; Takayama, H.; Sakai, S.; Aimi, N.; Watanabe, H. Suppressive effect of mitragynine on the 5-methoxy-N, N-dimethyltryptamine- induced head-twitch response in mice. Pharmacol. Biochem. Behav., 1997, 57, 319-323. (Pubitemid 27261428)
51. Tricklebank, M. D.; Forler, C.; Middlemiss, D. N.; Fozard, J. R. Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N, N-dimethyltryptamine in the rat. Eur. J. Pharmacol., 1985, 117, 15-24. (Pubitemid 16204495)
52. Eison, A. S.; Wright, R. N. 5-HT1A and 5-HT2 receptors mediate discrete behaviors in the Mongolian gerbil. Pharmacol. Biochem. Behav., 1992, 43, 131-137.
53. Cancela, L. M.; Volosin, M.; Molina, V. A. Gangliosides attenuate stress-induced changes on body weight, motor activity and on the behavioral response to 5-methoxy-N, N-dimethyltryptamine. Brain. Res. Bull., 1996, 40, 105-110. (Pubitemid 26158329)
54. Sanchez, C.; Arnt, J.; Moltzen, E. Assessment of relative efficacies of 5-HT1A receptor ligands by means of in vivo animal models. Eur. J. Pharmacol., 1996, 315, 245-254. (Pubitemid 26414269)
55. Krebs-Thomson, K.; Ruiz, E. M.; Masten, V.; Buell, M.; Geyer, M. A. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl), 2006, 189, 319-329. (Pubitemid 44772815)
56. Knapp, D. J.; Sim-Selley, L. J.; Breese, G. R.; Overstreet, D. H. Selective breeding of 5-HT (1A) receptor-mediated responses: application to emotion and receptor action. Pharmacol. Biochem. Behav., 2000, 67, 701-708. (Pubitemid 32144920)
57. Fox, M. A.; Andrews, A. M.; Wendland, J. R.; Lesch, K. P.; Holmes, A.; Murphy, D. L. A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. Psychopharmacology (Berl), 2007, 195, 147-166. (Pubitemid 350045849)
58. Fantegrossi, W. E.; Harrington, A. W.; Eckler, J. R.; Arshad, S.; Rabin, R. A.; Winter, J. C.; Coop, A.; Rice, K. C.; Woods, J. H. Hallucinogen-like actions of 2, 5-dimethoxy-4-(n) - propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl), 2005, 181, 496-503. (Pubitemid 41480898)
59. Matsumoto, K.; Morishige, R.; Murakami, Y.; Tohda, M.; Takayama, H.; Sakakibara, I.; Watanabe, H. Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: behavioural and electrophysiological studies. Eur. J. Pharmacol., 2005, 517, 191-199. (Pubitemid 40977895)
60. Halberstadt, A. L.; Buell, M. R.; Masten, V. L.; Risbrough, V. B.; Geyer, M. A. Modification of the effects of 5-methoxy-N, N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl), 2008, 201, 55-66.
61. Gudelsky, G. A.; Koenig, J. I.; Jackman, H.; Meltzer, H. Y. Suppression of the hypo-and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors. Psychopharmacology (Berl), 1986, 90, 403-407. (Pubitemid 16022479)
62. Gudelsky, G. A.; Koenig, J. I.; Meltzer, H. Y. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology, 1986, 25, 1307-1313. (Pubitemid 17228209)
63. Nagai, F.; Nonaka, R.; Satoh Hisashi Kamimura, K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol., 2007, 559, 132-137. (Pubitemid 46295399)
64. Nonaka, R.; Nagai, F.; Ogata, A.; Satoh, K. In vitro screening of psychoactive drugs by [(35) S]GTPgammaS binding in rat brain membranes. Biol. Pharm. Bull., 2007, 30, 2328-2333. (Pubitemid 350223736)
65. Wallach, J. V. Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception. Med. Hypotheses, 2009, 72, 91-94.
66. Suzuki, O.; Katsumata, Y.; Oya, M. Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase. Biochem. Pharmacol., 1981, 30, 1353-1358. (Pubitemid 11035402)
67. Raynaud, F.; Pevet, P. 5-Methoxytryptamine is metabolized by monoamine oxidase A in the pineal gland and plasma of golden hamsters. Neurosci. Lett., 1991, 123, 172-174.
68. Fuller, R. W.; Snoddy, H. D.; Perry, K. W. Tissue distribution, metabolism and effects of bufotenine administered to rats. Neuropharmacology, 1995, 34, 799-804.
69. Yu, A. M.; Granvil, C. P.; Haining, R. L.; Krausz, K. W.; Corchero, J.; Kupfer, A.; Idle, J. R.; Gonzalez, F. J. The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. J. Pharmacol. Exp. Ther., 2003, 304, 539-546. (Pubitemid 36152328)
70. Agurell, S.; Holmstedt, B.; Lindgren, J. E. Metabolism of 5-methoxy-N,-N dimethyltryptamine-14 C in the rat. Biochem. Pharmacol., 1969, 18, 2771-2781.
71. Sitaram, B. R.; Lockett, L.; Blackman, G. L.; McLeod, W. R. Urinary excretion of 5-methoxy-N, N-dimethyltryptamine, N, N-dimethyltryptamine and their N-oxides in the rat. Biochem. Pharmacol., 1987, 36, 2235-2237. (Pubitemid 17101743)
72. Sitaram, B. R.; Lockett, L.; Talomsin, R.; Blackman, G. L.; McLeod, W. R. In vivo metabolism of 5-methoxy-N, N-dimethyltryptamine and N, N-dimethyltryptamine in the rat. Biochem. Pharmacol., 1987, 36, 1509-1512. (Pubitemid 17079563)
73. Sitaram, B. R.; McLeod, W. R. Observations on the metabolism of the psychotomimetic indolealkylamines: implications for future clinical studies. Biol. Psychiatry, 1990, 28, 841-848.
74. Sitaram, B. R.; Talomsin, R.; Blackman, G. L.; McLeod, W. R. Study of metabolism of psychotomimetic indolealkylamines by rat tissue extracts using liquid chromatography. Biochem. Pharmacol., 1987, 36, 1503-1508. (Pubitemid 17079562)
75. Shen, H. W.; Jiang, X. L.; Yu, A. M. Development of a LC-MS/MS method to analyze 5-methoxy-N, N-dimethyltryptamine and bufotenine: application to pharmacokinetic study. Bioanalysis, 2009, 1, 87-95.
76. Ott, J. Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J. Psychoactive Drugs, 2001, 33, 273-281. (Pubitemid 32979643)
77. McBride, M. C. Bufotenine: toward an understanding of possible psychoactive mechanisms. J. Psychoactive Drugs, 2000, 32, 321-331.
78. Vogel, W. H.; Evans, B. D. Structure-activity-relationships of certain hallucinogenic substances based on brain levels. Life Sci., 1977, 20, 1629-1635. (Pubitemid 8119934)
79. Fabing, H. D.; Hawkins, J. R. Intravenous bufotenine injection in the human being. Science, 1956, 123, 886-887.
80. McLeod, W. R.; Sitaram, B. R. Bufotenine reconsidered. Acta. Psychiatr. Scand., 1985, 72, 447-450. (Pubitemid 16173562)
81. Yu, A. M.; Idle, J. R.; Byrd, L. G.; Krausz, K. W.; Kupfer, A.; Gonzalez, F. J. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics, 2003, 13, 173-181. (Pubitemid 36324247)
82. Chilton, W. S.; Bigwood, J.; Jensen, R. E. Psilocin, bufotenine and serotonin: historical and biosynthetic observations. J. Psychedelic Drugs, 1979, 11, 61-69. (Pubitemid 9256353)
83. Kostakis, C.; Byard, R. W. Sudden death associated with intravenous injection of toad extract. Forensic Sci. Int., 2009, 188, e1-5.
84. Zanger, U. M.; Raimundo, S.; Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol., 2004, 369, 23-37. (Pubitemid 38161221)
85. Loovers, H. M.; van der Weide, J. Implementation of CYP2D6 genotyping in psychiatry. Expert Opin. Drug Metab. Toxicol., 2009, 5, 1065-1077.
86. Dorado, P.; Penas-Lledo, E. M.; Llerena, A. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics, 2007, 8, 1597-1608. (Pubitemid 350286402)
87. De Gregori, M.; Allegri, M.; De Gregori, S.; Garbin, G.; Tinelli, C.; Regazzi, M.; Govoni, S.; Ranzani, G. N. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr. Drug Metab., 2010, 11, 276-282.
88. Migliaccio, G. P.; Shieh, T. L.; Byrn, S. R.; Hathaway, B. A.; Nichols, D. E. Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. J. Med. Chem., 1981, 24, 206-209. (Pubitemid 12212073)
89. Berger, G.; Maziere, M.; Marazano, C.; Comar, D. Carbon 11 labeling of the psychoactive drug o-methyl-bufotenine and its distribution in the animal organism. Eur. J. Nucl. Med., 1978, 3, 101-104. (Pubitemid 8300377)
90. Barker, S. A.; Littlefield-Chabaud, M. A.; David, C. Distribution of the hallucinogens N, N-dimethyltryptamine and 5-methoxy-N, N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method. J. Chromatogr. B. Biomed. Sci. Appl., 2001, 751, 37-47. (Pubitemid 32146312)
91. Sanders-Bush, E.; Oates, J. A.; Bush, M. T. Metabolism of bufotenine-2'-14C in human volunteers. Life Sci., 1976, 19, 1407-1411.
92. Boobis, A.; Watelet, J. B.; Whomsley, R.; Benedetti, M. S.; Demoly, P.; Tipton, K. Drug interactions. Drug Metab. Rev., 2009, 41, 486-527.
93. Yu, A. M. Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opin. Drug Metab. Toxicol., 2009, 5, 1513-1528.
94. He, S. M.; Yang, A. K.; Li, X. T.; Du, Y. M.; Zhou, S. F. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin. Drug Metab. Toxicol., 2010, 6, 1195-1213.
95. Ulbricht, C.; Chao, W.; Costa, D.; Rusie-Seamon, E.; Weissner, W.; Woods, J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr. Drug Metab., 2008, 9, 1063-1120.
96. Abdel-Fattah, A. F.; Matsumoto, K.; Gammaz, H. A.; Watanabe, H. Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism. Pharmacol. Biochem. Behav., 1995, 52, 421-426.
97. Glennon, R. A.; Dukat, M.; Grella, B.; Hong, S.; Costantino, L.; Teitler, M.; Smith, C.; Egan, C.; Davis, K.; Mattson, M. V. Binding of beta-carbolines and related agents at serotonin (5-HT (2) and 5-HT (1A)), dopamine (D (2)) and benzodiazepine receptors. Drug Alcohol Depend., 2000, 60, 121-132. (Pubitemid 30625015)
98. Tanaka, E.; Kamata, T.; Katagi, M.; Tsuchihashi, H.; Honda, K. A fatal poisoning with 5-methoxy-N, N-diisopropyltryptamine, foxy. Forensic Sci. Int., 2006, 163, 152-154. (Pubitemid 44442804)
99. Bjornstad, K.; Hulten, P.; Beck, O.; Helander, A. Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials. Clin. Toxicol. (Phila), 2009, 47, 566-572.
100. Kim, H.; Sablin, S. O.; Ramsay, R. R. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch. Biochem. Biophys., 1997, 337, 137-142. (Pubitemid 27198065)
101. Monsef, H. R.; Ghobadi, A.; Iranshahi, M.; Abdollahi, M. Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test. J. Pharm. Pharm. Sci., 2004, 7, 65-69. (Pubitemid 38628938)
102. Hilber, P.; Chapillon, P. Effects of harmaline on anxiety-related behavior in mice. Physiol. Behav., 2005, 86, 164-167. (Pubitemid 41316620)
103. Moura, D. J.; Rorig, C.; Vieira, D. L.; Henriques, J. A.; Roesler, R.; Saffi, J.; Boeira, J. M. Effects of beta-carboline alkaloids on the object recognition task in mice. Life Sci., 2006, 79, 2099-2104. (Pubitemid 44573274)
104. Hutchinson, D.; Ho, V.; Dodd, M.; Dawson, H. N.; Zumwalt, A. C.; Schmitt, D.; Colton, C. A. Quantitative measurement of postural sway in mouse models of human neurodegenerative disease. Neuroscience, 2007, 148, 825-832. (Pubitemid 47419200)
105. Paterson, N. E.; Malekiani, S. A.; Foreman, M. M.; Olivier, B.; Hanania, T. Pharmacological characterization of harmaline-induced tremor activity in mice. Eur. J. Pharmacol., 2009, 616, 73-80.
106. Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet., 2009, 48, 761-804.
107. Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 2009, 48, 689-723.
108. Narimatsu, S.; Yonemoto, R.; Saito, K.; Takaya, K.; Kumamoto, T.; Ishikawa, T.; Asanuma, M.; Funada, M.; Kiryu, K.; Naito, S.; Yoshida, Y.; Yamamoto, S.; Hanioka, N. Oxidative metabolism of 5-methoxy-N, N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem. Pharmacol., 2006, 71, 1377-1385.
109. Corchero, J.; Granvil, C. P.; Akiyama, T. E.; Hayhurst, G. P.; Pimprale, S.; Feigenbaum, L.; Idle, J. R.; Gonzalez, F. J. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol. Pharmacol., 2001, 60, 1260-1267. (Pubitemid 33144897)
110. Gonzalez, F. J.; Yu, A. M. Cytochrome P450 and xenobiotic receptor humanized mice. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 41-64. (Pubitemid 43271183)
111. Lin, J. H. Applications and limitations of genetically modified mouse models in drug discovery and development. Curr. Drug. Metab., 2008, 9, 419-438. (Pubitemid 352025196)
112. Yu, A. M.; Idle, J. R.; Krausz, K. W.; Kupfer, A.; Gonzalez, F. J. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J. Pharmacol. Exp. Ther., 2003, 305, 315-322. (Pubitemid 36373866)
113. Wu, C.; Jiang, X. L.; Shen, H. W.; Yu, A. M. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem. Pharmacol., 2009, 78, 617-624.